Breaking News, Collaborations & Alliances

GigaGen Initiates Large-Scale Manufacturing of GIGA-2050

A recombinant hyperimmune drug for COVID-19.

By: Contract Pharma

Contract Pharma Staff

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, has initiated large-scale manufacturing of its recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), Waisman Biomanufacturing and Goodwin Biotechnology Inc.   Large scale production of GIGA-2050 will support an Investigational New Drug application (IND) and Phase 1 st...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters